Enteric Disease Testing Market Analysis by Test Type, Technology and Forecast, 2026–2034

Author : Mahesh Chavan | Published On : 25 Jun 2026

The global enteric disease testing market is witnessing sustained growth as healthcare systems worldwide prioritize the early detection and management of gastrointestinal infections. Increasing incidences of bacterial, viral, and parasitic enteric diseases, coupled with growing awareness regarding diagnostic testing and disease surveillance, are creating favorable conditions for market expansion.

According to recent industry analysis, the global enteric disease testing market was valued at USD 4.17 billion in 2025 and is projected to grow from USD 4.43 billion in 2026 to USD 7.25 billion by 2034, registering a compound annual growth rate (CAGR) of 6.33% during the forecast period.

The market's growth is being driven by the rising prevalence of infectious gastrointestinal diseases, increasing healthcare expenditures, advancements in diagnostic technologies, and expanding public health initiatives focused on disease prevention and outbreak control. Enteric disease testing plays a critical role in identifying pathogens responsible for infections affecting the gastrointestinal tract, enabling healthcare professionals to implement appropriate treatment strategies and limit disease transmission.

As foodborne and waterborne infections continue to impact millions of people annually, healthcare providers, research institutions, and diagnostic companies are investing in advanced testing solutions that deliver faster, more accurate, and reliable results.

Growing Burden of Enteric Infections Fuels Market Demand

The increasing incidence of enteric infections worldwide remains one of the most significant drivers of market growth. Factors such as rapid urbanization, population growth, globalization of food supply chains, inadequate sanitation, and limited access to clean water continue to contribute to the spread of gastrointestinal pathogens.

Enteric diseases caused by bacteria, viruses, and parasites frequently result in symptoms such as diarrhea, vomiting, abdominal pain, fever, and dehydration. In severe cases, these infections can lead to hospitalization or death, particularly among children, older adults, and immunocompromised individuals.

Global health organizations continue to highlight the burden of diarrheal diseases as a major public health challenge. Outbreaks involving cholera, typhoid fever, shigellosis, salmonellosis, and Escherichia coli infections have reinforced the need for effective diagnostic testing capabilities across healthcare systems.

Recent reports of cholera outbreaks, typhoid fever cases, and increasing incidences of foodborne illnesses across multiple regions have further emphasized the importance of timely diagnosis and disease monitoring. Healthcare authorities increasingly recognize that rapid and accurate enteric disease testing is essential for outbreak management, treatment decisions, and public health interventions.

Diagnostic Innovation Enhances Testing Capabilities

Technological advancements continue to transform the enteric disease testing landscape. Modern diagnostic platforms are delivering improved accuracy, shorter turnaround times, and the ability to identify multiple pathogens simultaneously.

Healthcare laboratories are increasingly adopting advanced molecular diagnostic techniques that enable precise pathogen detection. These technologies help clinicians identify causative organisms quickly, reducing delays in treatment and improving patient outcomes.

At the same time, immunodiagnostic testing methods remain widely used due to their reliability, accessibility, and cost-effectiveness. Technologies such as enzyme-linked immunosorbent assays (ELISAs), lateral flow assays, and immunofluorescence assays continue to support routine diagnostic workflows across hospitals and laboratories.

The growing integration of automation within diagnostic laboratories is also improving testing efficiency, enabling healthcare providers to process larger sample volumes while maintaining high levels of accuracy.

Limited Healthcare Access Remains a Key Challenge

Despite positive market momentum, limited access to healthcare services and diagnostic infrastructure continues to pose a significant challenge in many parts of the world.

Several low- and middle-income countries face shortages of healthcare facilities, trained laboratory personnel, and advanced diagnostic equipment. As a result, many enteric disease cases remain undiagnosed or underreported, impacting disease surveillance and public health response efforts.

In numerous resource-constrained regions, healthcare providers continue to rely on clinical diagnosis or traditional testing methods due to the lack of access to modern diagnostic technologies. This can delay treatment and increase the risk of disease transmission within communities.

Rural populations often face additional barriers, including transportation challenges, limited healthcare access, and inadequate laboratory infrastructure. These factors highlight the need for affordable and scalable diagnostic solutions capable of reaching underserved populations.

Point-of-Care Testing Creates New Growth Opportunities

One of the most promising developments in the enteric disease testing market is the rapid expansion of point-of-care testing (POCT).

Healthcare providers are increasingly seeking decentralized diagnostic solutions that can deliver accurate results closer to patients. Point-of-care testing technologies offer significant advantages, particularly in remote locations, outbreak situations, and healthcare environments with limited laboratory infrastructure.

Portable molecular testing devices, rapid diagnostic tests, and lab-on-a-chip technologies are helping improve access to timely diagnosis while reducing dependence on centralized laboratories. These solutions support faster clinical decision-making and enable healthcare workers to respond more effectively to infectious disease outbreaks.

Growing investments by governments, international health organizations, and non-governmental organizations are further supporting the deployment of point-of-care testing solutions in underserved regions. As healthcare systems continue prioritizing early diagnosis and disease surveillance, POCT is expected to become an increasingly important component of enteric disease management strategies.

Reagents and Consumables Lead Product Segment

Based on product type, the reagents and consumables segment currently accounts for the largest share of the global enteric disease testing market.

These products form the foundation of diagnostic workflows and are required for sample preparation, nucleic acid extraction, pathogen detection, assay development, and result generation. The recurring demand for testing reagents and consumables across laboratories, hospitals, and research facilities continues to support segment growth.

Meanwhile, the equipment segment is anticipated to register the fastest growth during the forecast period. Increasing demand for automated laboratory systems, advanced molecular diagnostic platforms, and high-throughput testing technologies is driving investments in modern diagnostic equipment.

Healthcare organizations are increasingly seeking solutions that can process multiple samples simultaneously while delivering highly accurate results within shorter timeframes.

Molecular Diagnostics Gains Momentum

Among testing techniques, immunodiagnostics currently holds a substantial market share due to widespread adoption and ongoing technological improvements.

However, molecular diagnostics is expected to emerge as the fastest-growing segment over the coming years. Growing demand for highly sensitive and specific testing methods is accelerating the adoption of molecular diagnostic technologies across clinical laboratories and research institutions.

Techniques such as polymerase chain reaction (PCR) testing enable healthcare professionals to identify pathogens with exceptional precision, supporting improved patient management and disease surveillance efforts.

The increasing availability of molecular diagnostic equipment and the expansion of research activities focused on infectious disease detection are expected to further strengthen segment growth.

Bacterial Enteric Diseases Continue to Drive Testing Demand

Bacterial enteric diseases represent the largest disease-type segment within the market. Rising incidences of infections caused by pathogens such as Salmonella, Clostridium difficile, Helicobacter pylori, Campylobacter, and Escherichia coli continue to generate substantial demand for diagnostic testing solutions.

These infections remain significant public health concerns due to their association with contaminated food, water, and inadequate sanitation. As awareness of bacterial enteric diseases increases globally, demand for accurate diagnostic testing is expected to remain strong.

Viral and parasitic enteric diseases also contribute significantly to market demand, particularly in regions experiencing recurring outbreaks and poor sanitation conditions.

Hospital Laboratories Remain the Primary End Users

Hospital laboratories account for the largest share of the enteric disease testing market and are expected to maintain their leadership position throughout the forecast period.

These facilities play a critical role in diagnosing gastrointestinal infections and supporting clinical decision-making. Growing patient volumes, increased testing rates, and greater awareness regarding routine health screenings continue to support segment growth.

Pharmaceutical and biotechnology companies are also contributing to market development through ongoing investments in research and development. These organizations are actively working to develop innovative diagnostic technologies, improve assay performance, and expand testing capabilities for a broader range of enteric pathogens.

North America Leads While Asia-Pacific Emerges as Fastest-Growing Region

North America currently dominates the global enteric disease testing market, supported by advanced healthcare infrastructure, strong reimbursement frameworks, significant research investments, and the presence of major diagnostic companies.

The United States remains a key contributor to regional growth due to increasing disease awareness, widespread adoption of advanced diagnostic technologies, and favorable healthcare spending patterns.

Europe continues to represent a significant market, supported by an aging population, growing demand for rapid diagnostics, and expanding healthcare investments.

Meanwhile, Asia-Pacific is expected to record the fastest growth during the forecast period. Rising infection rates, expanding healthcare infrastructure, increasing public awareness, and improving access to diagnostic services are creating substantial opportunities across countries such as China, India, and other emerging economies.

Competitive Landscape Focuses on Innovation and Expansion

The enteric disease testing market remains highly competitive, with leading companies focusing on product innovation, strategic acquisitions, regulatory approvals, and technological advancements.

Major market participants include Abbott Laboratories, Bio-Rad Laboratories Inc., Diasorin SpA, Trinity Biotech, Meridian Bioscience Inc., Coris BioConcept, Quest Diagnostics Inc., Biomerica Inc., Biomerieux SA, and Becton Dickinson & Company.

Recent developments underscore the industry's commitment to innovation. In 2024, Abbott received FDA clearance for a whole blood rapid test designed to assist in bedside concussion assessment. Diasorin submitted its LIAISON PLEX® Yeast Blood Culture Assay to the U.S. Food and Drug Administration, while Trinity Biotech announced the acquisition of continuous glucose monitoring assets from Waveform Technologies.

As healthcare systems increasingly prioritize infectious disease surveillance and rapid diagnostics, the enteric disease testing market is expected to play an essential role in improving global public health outcomes and strengthening healthcare preparedness.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/enteric-disease-testing-market

About Straits Research

Straits Research is a global market research and consulting organization dedicated to delivering actionable business intelligence, industry analysis, and strategic insights across diverse sectors. The company provides comprehensive market reports that help organizations identify emerging opportunities, evaluate competitive dynamics, understand industry trends, and make informed business decisions. Leveraging rigorous research methodologies, data-driven analysis, and extensive industry expertise, Straits Research empowers businesses, investors, and stakeholders to navigate evolving markets and achieve sustainable growth.